Skip to main content
Assets
Abbott Laboratories logo
ABT.NYSE
Abbott Laboratories
Health Care · Health Care Equipment

Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

HQ: United StatesListed: United States

Profile & Fundamentals

Abbott Laboratories: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.

Profile & Fundamentals

Abbott Laboratories Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Company and Market Context

Company Profile & Ownership

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

ABT.NYSE

Company profile record

Abbott Laboratories

Common Stock · Health Care · Health Care Equipment

Official website

Company

Company / asset
Abbott Laboratories
Security type
Common Stock
Sector
Health Care
Industry
Health Care Equipment
HQ
🇺🇸 United States
Head office
100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400

Leadership & scale

Chief executive
Mr. Robert B. Ford
CEO year born
1974
Full-time employees
122K
Fiscal year end
December
IPO date
1978-01-13

Fundamentals snapshot

Updated 2026-09-30
Market Cap
USD 171.1B
P/E
31.5x
Revenue (Q2 26)
USD 12.6B
Profit (Q2 26)
USD 928.0M
Dividend Yield
1.8%
Revenue (FY 25)
USD 44.3B
Shares in public float
1.7B
Insider ownership
0.49%

Reporting & identifiers

Symbol
ABT.NYSE
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US0028241000
Asset ID
equity_90606491-6d1d-54e4-989e-78da2d2dbfa6

Ownership

Shares Outstanding

Latest: 1.7B | Max: 1.8B | Min: 1.7B

Shares Outstanding
2.3B1.7B1.1B563.5M0.00
1.7B
'17
'19
'21
'23
'25
'26

Latest reported ownership snapshot

As of Oct 1, 2026

Float Shares

98.67%

1.7B latest reported shares

Insider Ownership

0.49%

Latest reported insider stake

Short Float

0.01%

Latest reported short interest / float

Top Holders

Top 5 concentration: 25.52%
BlackRock Inc
institution
Filed 2026-03-31 • Change -1.2M (-0.83%)
8.42%(145.7M shares)
Vanguard Capital Management, LLC
institution
Filed 2026-03-31 • Change +112.9M (0.00%)
6.53%(112.9M shares)
State Street Corp
institution
Filed 2026-03-31 • Change -278.3K (-0.35%)
4.60%(79.6M shares)
Vanguard MStar Total Stk Mkt Idx Invest
fund
Filed 2026-08-31 • Change -108.7K (-0.20%)
3.20%(55.4M shares)
Vanguard Portfolio Management, LLC
institution
Filed 2026-03-31 • Change +47.9M (0.00%)
2.77%(47.9M shares)
Schwab US Dividend Equity ETF™
fund
Filed 2026-08-29 • Change +119.0K (+0.25%)
2.75%(47.6M shares)
Vanguard 500 Index Investor
fund
Filed 2026-08-31 • Change +548.9K (+1.20%)
2.67%(46.3M shares)
Source tablesView ownership tables

Shares Outstanding

Annual reported shares outstanding; up to 10 reporting dates.

Scroll the table to see every column.

Shares outstanding — reported values
Reporting dateShares outstanding
2017-01-011,746,000,000
2018-01-011,774,000,000
2019-01-011,781,000,000
2020-01-011,789,000,000
2021-01-011,782,000,000
2022-01-011,754,000,000
2023-01-011,748,000,000
2024-01-011,746,000,000
2025-01-011,747,000,000
2026-01-011,743,000,000

Top Holders

Available reported ownership records.

Scroll the table to see every column.

Largest reported holders
HolderSharesOwnershipReported date
BlackRock Inc145,687,4588.42%2026-03-31
Vanguard Capital Management, LLC112,949,9336.53%2026-03-31
State Street Corp79,575,4684.6%2026-03-31
Vanguard MStar Total Stk Mkt Idx Invest55,355,4503.2%2026-08-31
Vanguard Portfolio Management, LLC47,944,8912.77%2026-03-31
Schwab US Dividend Equity ETF™47,574,8422.75%2026-08-29
Vanguard 500 Index Investor46,275,7542.67%2026-08-31
Charles Schwab Investment Management Inc45,500,0552.63%2026-03-31
Geode Capital Management, LLC39,148,7952.26%2026-03-31
Capital Research Global Investors36,908,9902.13%2026-06-30
Capital Research & Mgmt Co - Division 334,654,1132%2026-06-30
Morgan Stanley - Brokerage Accounts30,101,5961.74%2026-03-31
JPMorgan Chase & Co26,767,0991.55%2026-03-31
NORGES BANK23,354,9111.35%2026-06-30
iShares Core S&P 500 ETF23,201,9021.34%2026-08-31

Earnings, Profitability & Valuation

Earnings, Profitability & Valuation

Earnings & Revenue

Earnings and Revenue Trajectory

AI Review

Abbott's recent financial headlines look deceptive at first glance. Reported accounting profit fell sharply in mid-2026, but this drop was caused by non-operating legal settlement reserves and purchase-accounting charges from acquiring Exact Sciences rather than slowing customer sales. In fact, underlying business revenue climbed to forty-six point six billion dollars over the trailing twelve months, powered by resilient high-single-digit growth across medical devices and branded generic medicines. The true operational health appears in cash generation. Abbott produced nearly eight billion dollars in trailing free cash flow, showing that its core commercial engine remains exceptionally profitable. As acquisition integration charges fade, headline earnings will re-align with cash flows, supporting steady long-term compounding.

Revenue, Net Income, and Free Cash Flow

Latest: USD 44.3B | Max: USD 44.3B | Min: USD 477.0M

RevenueFree Cash FlowNet Income
USD 55.9BUSD 41.9BUSD 27.9BUSD 14.0BUSD 0.00
44.3B
7.4B
6.5B
'16
'18
'20
'22
'24
'25

Valuation

P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.

Latest: 34x

39x29x20x10x0x
35x
34x
34x
'21'23'25

Profitability & Margins

Margins and Operating Efficiency

AI Review

Abbott's profitability reveals an underlying improvement in product quality. Adjusted gross margins widened toward fifty-eight percent in mid-2026, driven by a favorable mix shift toward high-margin medical devices, glucose sensors, and precision oncology screening. These proprietary medical products carry strong pricing power, effectively counteracting raw-material inflation, hospital budget constraints, and international tariff headwinds. Although reported net income margins dipped temporarily due to acquisition financing and legal accruals, operating margins are positioned to recover toward twenty percent. As one-off merger expenses subside and automated manufacturing lowers unit sensor costs, operational leverage will drive accelerated profit growth across the five-year investment horizon.

Profitability Margins

Latest: 55.5% | Max: 55.5% | Min: 1.7%

Gross MarginOperating MarginNet Margin
69.9%52.5%35.0%17.5%0.0%
55.5%
18.2%
14.7%
'16
'18
'20
'22
'24
'25

Latest Profitability Ratios as of 2025-12-31

Gross Margin

55.5%

Gross profit / revenue

Operating Margin

18.2%

Operating income / revenue

Net Margin

14.7%

Net income / revenue

FCF Margin

16.7%

Free cash flow / revenue

Source tablesView earnings, profitability & valuation tables

Revenue, Net Income, and Free Cash Flow

Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.

Scroll the table to see every column.

Annual earnings and cash flow
Period endRevenue (USD)Net income (USD)Free cash flow (USD)
2016-12-3120,853,000,0001,400,000,0002,082,000,000
2017-12-3127,390,000,000477,000,0004,435,000,000
2018-12-3130,578,000,0002,368,000,0004,906,000,000
2019-12-3131,904,000,0003,687,000,0004,498,000,000
2020-12-3134,608,000,0004,495,000,0005,724,000,000
2021-12-3143,075,000,0007,071,000,0008,648,000,000
2022-12-3143,653,000,0006,933,000,0007,804,000,000
2023-12-3140,109,000,0005,723,000,0005,059,000,000
2024-12-3141,950,000,00013,402,000,0006,351,000,000
2025-12-3144,328,000,0006,524,000,0007,395,000,000

Published P/E Ratio

Published valuation snapshots retain each observation's earnings basis.

Scroll the table to see every column.

Published valuation snapshots
Period endP/E (times earnings)Earnings basis
2025-12-3133.55Trailing four quarters
2024-12-3114.74Trailing four quarters
2023-12-3133.62Trailing four quarters
2022-12-3127.78Annual net income
2021-12-3135.47Annual net income

Profitability Margins

Matching annual reporting dates. Values are percentages.

Scroll the table to see every column.

Annual profitability margins
Period endGross margin (%)Operating margin (%)Net margin (%)Free cash flow margin (%)
2016-12-3153.9215.586.719.98
2017-12-3147.77.21.7416.19
2018-12-3151.7512.577.7416.04
2019-12-3152.3214.3911.5614.1
2020-12-3150.2115.2912.9916.54
2021-12-3153.8921.3616.4220.08
2022-12-3151.1419.1615.8817.88
2023-12-3149.9616.0414.2712.61
2024-12-3150.8316.2731.9515.14
2025-12-3155.5118.1614.7216.68

Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-10-01.

Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.